Please provide your email address to receive an email when new articles are posted on . At the Congress on Controversies in Ophthalmology, Lee and Susan Mollan, MBChB, FRCOphth, PhD, debated this ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GCA diagnoses made via temporal artery ultrasound were ...
Other major complications of GCA include stroke, MI, aortic aneurysm, and visceral organ infarcts due to the occlusion of large arteries. 1,4 While early diagnosis and treatment may decrease the ...
At week 52 in a randomized, controlled trial, results suggest that tocilizumab is more effective than methotrexate in ...
In one study of 161 patients with biopsy-proven GCA followed up for 11 years, the prevalence of visual ischemic complications was 26.1% and the prevalence of irreversible blindness, mainly due to ...
Out of 165 older patients in whom GCA was strongly suspected, 73 (44%) had the telltale "halo" sign on temporal artery ultrasound; and of those, the GCA diagnosis was unchanged when re-examined 2 ...
Recent advances in the study of inflammatory vasculitides have underscored the complexity of both giant cell arteritis (GCA) and Takayasu arteritis (TAK). Research has increasingly revealed the ...
SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck. Symptoms include, head ...
Explore causes, symptoms and diagnosis of Giant Cell Arteritis and Temporal Arteritis including headache, vision loss and jaw ...
Learn about polymyalgia rheumatica, temporal arteritis, their symptoms, causes, and treatment options to manage pain, ...
Results from the trial's first year were reported at the 2024 ACR meeting, and they persuaded the FDA to approve the drug for ...
Disease-associated vision changes are common in GCA, with no significant difference in visual improvement observed with IV glucocorticoids vs oral therapy.